The Swiss group shells out $2bn for Synnovation’s mutation-selective PI3Kα inhibitor.
ApexOnco Front Page
Recent articles
A unique VEGF trispecific and mRNA-based T-cell engager will also be featured at the congress.
PersonGen’s LV009 takes the industry tally of clinical-stage projects to 14.
The holiday period included Genmab’s discontinuation of acasunlimab.
Nenocorilant features among the latest industry projects newly into phase 1.
A deal with Jacobio is worth $100m up front.
Two new PD-(L)1 x VEGF projects have entered the clinic.
In fit KMT2Ar patients the group will focus on Revuforj plus Venclexta and azacitidine.
